SAN FRANCISCO, March 22, 2018 /PRNewswire/ -- Invitae
Corporation (NYSE: NVTA), one of the fastest growing genetic
information companies, today announced an expansion of its network
of rare and ultra-rare patient registries in its Patient Insights
NetworkTM (PIN) program to include five additional
collaborations with leading advocacy groups across a variety of
genetic conditions. The programs are designed to empower patients
to be active participants in their networks and further expand
Invitae's work to connect patients with rare genetic disorders to
research, clinical trials and information on managing their
condition.
The first PIN to launch is led by No Stomach For Cancer, a
leading research and advocacy organization focused on stomach
cancer. Known as the Global Gastric Cancer Registry, the program
enables patients, advocates, clinicians and researchers to share
and access deidentified data on a number of different stomach
cancers, including Diffuse Gastric Cancer, Proximal Stomach Cancer
and Noncardia (Distal) Stomach Cancer.
"Having access to information on clinical experience and
outcomes continues to help improve care for patients and
accelerates access to clinical trials for both patients and
researchers. These networks are making a powerful contribution to
advancing our understanding of diseases, particularly in rare
disorders." said Robert Nussbaum,
M.D., chief medical officer of Invitae. "We're proud of our
collaborations with these organizations and their membership to
empower patients and help advance research and improve support for
people living with these rare conditions."
"Two of the many important ways we can help patients and
families facing stomach cancer are to connect them with research
opportunities and to help them better understand their condition,"
said Jon Florin, Executive Director
at No Stomach For Cancer. "Our registry program will help the
global gastric cancer community by better characterizing how
stomach cancer is currently treated through patient provided
outcomes, as well as by connecting researchers with patients who
may benefit from new therapies. The more people who join the Global
Gastric Cancer Registry, the more the network will achieve."
People diagnosed with gastric cancer or a genetic predisposition
to gastric cancer may learn more and join the Global Gastric Cancer
Registry by visiting: http://gastriccancerregistry.org
In addition to the Global Gastric Cancer Registry, Invitae will
be partnering with four other leading advocacy groups to host and
launch additional Patient Insights Networks:
- The Bow Foundation will be launching a registry for patients
with GNAO1 disorders, an ultra-rare pediatric genetic
disorder causing developmental delays and neurological symptoms
impacting fewer than 100 people worldwide.
- A registry aimed at gathering data on the GM2 Gangliosidoses,
such as Tay Sachs disease and Sandhoff disease, rare
neurodegenerative lysosomal disorders, in partnership with the
National Tay Sachs & Allied Diseases Association (NTSAD).
- The RASopathies Network will launch a network aimed at
gathering information across a number of rare genetic conditions
associated with genetic variants in the Ras-MAPK pathway, that
cause developmental delays, heart defects and neurologic
problems.
- The Spastic Paraplegia Foundation is creating a network for
families impacted by Hereditary Spastic Paraplegia or Primary
Lateral Sclerosis, a group of rare primary upper motor neuron
disorders that cause progressive spasticity (stiffness) and
weakness of the leg and hip muscles.
Patient Insights Networks have reimagined the traditional
patient registry to maximize the ability of patients to contribute
and control their own data and amplify the impact that data can
have for other patients, clinicians and researchers. Patient
Insights Networks build powerful data sets of symptoms, history,
diagnostic journey, quality of life and cost of living with serious
health conditions. Patients, advocates, clinicians and researchers
then have access to the de-identified data and research-ready
patient communities to drive insights that can improve care,
increase access to clinical trials and accelerate treatment
development. Invitae's program currently covers more than 400
different health conditions. A complete listing of network partners
can be found at https://pindirectory.invitae.com/.
For more information visit
invitae.com/patient-insights-network.
About No Stomach for Cancer
No Stomach For Cancer, Inc. is a 501(c)(3) nonprofit organization
whose mission is to support research and unite the caring power of
people worldwide affected by stomach cancer. Serving families
across the globe, NSFC advances awareness and education about
stomach cancer, including Hereditary Diffuse Gastric Cancer (HDGC),
provides a support network for affected families, and supports
research for screening, early detection, treatment, and prevention
of stomach cancer. Headquartered in Wisconsin and serving families
across the globe, No Stomach For Cancer is a worldwide thought
leader in stomach cancer awareness and education. For more
information, please visit www.nostomachforcancer.org
About Invitae
Invitae Corporation (NYSE: NVTA) is bringing comprehensive genetic
information into mainstream medical practice to improve the quality
of healthcare for billions of people. As one of the fastest growing
genetic information companies, Invitae is advancing the broad
potential of genetics, helping to expand its use across the
healthcare continuum. The company provides genetic information
services for all stages of life – from preconception screening, to
newborn diagnosis, to inherited disease screening, to proactive
health management – and a unique, rapidly expanding network of
patients, hospital systems, and advocacy partners that is moving
genetics from one-dimensional testing to complex information
management. For more information visit www.invitae.com, or follow
us on Twitter, Facebook or LinkedIn.
Invitae Corporation Safe Harbor Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the benefits and effectiveness of
establishing PIN programs; the company's expectations regarding
future partnerships with advocacy groups; and the advocacy groups'
hosting and launching of the registry programs. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should
not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the
company's ability to utilize the registry information effectively;
the company's continued partnerships with advocacy groups; the risk
that the advocacy groups may not be able to launch, expand or
continue their registry programs; security breaches, loss of data
and other disruptions regarding information obtained from the
advocacy groups; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Annual Report on Form 10-K for the year
ended December 31, 2017. These
forward-looking statements speak only as of the date hereof, and
Invitae Corporation disclaims any obligation to update these
forward-looking statements.
Contact:
Laura D'Angelo
pr@invitae.com
314-920-0617
View original content with
multimedia:http://www.prnewswire.com/news-releases/invitae-expands-network-of-patients-in-rare-and-ultra-rare-diseases-300617975.html
SOURCE Invitae Corporation